A rapid serological screening method for detecting tuberculosis disease and monitoring the efficacy of new vaccines
The development of new diagnostic tools and more effective vaccines are essential to combat the global tuberculosis (TB) pandemic. The lack of a widely accessible screening test that is easy to perform without laboratory facilities is one of the main reasons for the unacceptable delay in diagnosing pulmonary TB. The goal of this project is to develop, evaluate and validate a rapid, sensitive and inexpensive serological test for the detection of TB disease that is suitable for use in the developing world.
It is crucial that a screening test detects only active disease because latent TB is prevalent, but not a target for treatment, in developing countries. Recent advances in proteomics and genomics make it possible to investigate a large repertoire of M. tuberculosis proteins for their ability to serve as diagnostic markers. Comparison of antigens recognized by antibodies from patients and community controls recruited from TB endemic regions will enable the identification of appropriate antigens that can be used to differentiate between active and latent infection. After demonstrating proof-of-principle the prototype ELISA assay will be transferred to a rapid assay platform and evaluated in the field by collaborative partners in settings with different TB epidemiology.
A rapid screening test will make it possible to identify and selectively treat those with active TB disease at the local health care level thus reducing diagnostic delay and transmission. In addition, the test will be designed to differentiate between TB and vaccine-induced immunity. Accurate diagnostic tools suitable for use in the developing world are essential for monitoring the efficacy of new candidate TB vaccines. The collaborative network and administrative structure of this project are designed to achieve ideal cross-institutional interactions between Western and developing countries, technology transfer, decentralization and increasing local capacity to curb TB in endemic regions.
See the full project description at Cristin for more information about results, researchers, contact information etc.
Abebe yimer solomon, Norwegian Institute of Public Health
Balthazar Melchior Nyombi, Kilimanjaro Christian Medical Centre
Bjørn Haneberg, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Gunnar Aksel Bjune, Department of Community Medicine and Global Health, University of Oslo
Hiwa Målen, University of Bergen
Harald G Wiker, Klinisk institutt 2, University of Bergen
Øistein Ihle, Norwegian Institute of Public Health
Gro Ellen Korsvold, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Fredrik Oftung, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Mecky I Matee, Muhimbili University of Health and Allied Sciences
Markos Abebe, AHRI Armauer Hansen Research Institute
Dick van Soolingen, National Institute for Public Health and the Environment
Shiferaw Bekele, AHRI Armauer Hansen Research Institute
Paul D. van Helden, University of Stellenbosch
Elena Hailu, AHRI Armauer Hansen Research Institute
Gerhard Walzl, University of Stellenbosch
Abraham Aseffa, AHRI Armauer Hansen Research Institute
Lizette Balle Petersen, Avdeling for infeksjonsimmunologi, Norwegian Institute of Public Health
Asma Elsony, EpiLab/Sudan National Tuberculosis and Leprosy Control Program
Vu Tan Trao, Viet Nam
Novel Chegou, University of Stellenbosch
Grant Theron, University of Stellenbosch
Nick Borain, South Africa